Lupus Research Alliance announces Lupus Research Highlights at ACR Convergence 2024

This information is brought to you by the Lupus Research Alliance and is not sponsored by, nor a part of, the American College of Rheumatology.

2024-11-04

(Press-News.org)

Lupus Research Alliance Announces Lupus Research Highlights

at ACR Convergence 2024

Sixteen presentations of preclinical studies funded by the Lupus Research Alliance (LRA) to advance understanding of lupus and potential treatment pathways, including four oral presentations Two reports by Lupus Therapeutics, the clinical affiliate of the LRA, and the Lupus Clinical Investigators Network (LuCIN) on promoting equity in lupus clinical trials, and identifying trial barriers and solutions Fifteen industry-sponsored clinical research studies supported by Lupus Therapeutics and LuCIN, including positive results from the late-breaking Phase 3 dapirolizumab pegol trial NEW YORK, November 4, 2024 – The Lupus Research Alliance (LRA), the largest private funder of lupus research worldwide, today announced that a total of 33 studies, funded by the organization or supported by its clinical research affiliate Lupus Therapeutics, will be presented at ACR Convergence 2024. The annual meeting of the American College of Rheumatology takes place November 14-19, at the Walter E. Washington Convention Center in Washington, D.C.

The LRA, which seeks to accelerate the discovery and development of patient-centered treatments and diagnostics, pursues strategies to spur advancements from “bench to bedside.” LRA-supported studies presented at ACR Convergence 2024 represent the full continuum of lupus research, from foundational research exploring new avenues of knowledge, to clinical trials evaluating potential new treatments.

“ACR Convergence 2024 is met with pride and excitement by the Lupus Research Alliance and Lupus Therapeutics – pride in seeing the fruits of our funding and other initiatives to accelerate drug discovery and development, and excitement as we stand on the precipice of some important advancements,” said LRA President and CEO Albert T. Roy.

“There are more trials in mid-to-late-stage development than ever before, including dapirolizumab pegol in Phase 3 from UCB/Biogen, a Lupus Therapeutics partner. And we are gratified to witness the volume of CAR T cell therapy approaches in clinical development, having invested in 2014 in early research suggesting this approach as a promising intervention to explore for treating lupus," Roy added.

Foundational Research Funded by the LRA

Sixteen studies of LRA-funded research (four oral presentations and 12 posters) will be presented. Several focus on Childhood-Onset Systemic Lupus Erythematosus (cSLE), including: a detailed characterization of the disease; the effects of fatigue on pediatric patients’ mental and physical health; and the discovery of Anti-Mitochondrial Antibodies (AMA), which are linked to higher disease activity.

Other studies include: the development of a precision immunotherapy to target harmful B cells in Antiphospholipid Syndrome (APS) patients; the discovery of innate signaling pathways crucial in causing inflammation in lupus patients; and the epidemiology of strokes in children and adults with lupus.

ORAL PRESENTATIONS

Saturday, Nov. 16

Abstract #0837: Bispecific Autoantigen-T Cell Engagers (BaiTE) to Selectively Target Autoreactive B Cells in Antiphospholipid Syndrome
3:00-3:15 PM, Room 103AB

Sunday, Nov. 17

Abstract #1702: Placental Developmental Defects in a Humanized-TLR8 Mouse Model of Spontaneous Anti-Phospholipid Antibody Induced Pregnancy Loss
3:15-3:30 PM, Room 103AB

Monday, Nov. 18

Xist and XChromosome Inactivation in Female Biased Autoimmunity
9:00-9:30 AM, Room 145AB

Abstract #2625: Brain Injury Markers Correlate with Impaired Executive Function and Disease Activity in Children with Systemic Lupus Erythematosus
3:30-3:45 PM, Room 202AB

POSTERS

Saturday, Nov. 16

Poster Session A, 10:30 AM-12:30 PM, Poster Hall:

Abstract #0091: Targeting Endothelial Dysfunction in Lupus Nephritis: Effect of Sepiapterin, a Drug That Restores Endothelial Nitric Oxide Synthase Function, in a Murine Model of Lupus Nephritis

Abstract #0098: Anti-HSP90α as a Protective Natural Antibody Against Secondary Antiphospholipid Syndrome in Systemic Lupus Erythematosus

Sunday, Nov. 17

Poster Session B, 10:30 AM-12:30 PM, Poster Hall:

Abstract #1266: Anti-Mitochondrial Antibodies Associate with Disease Activity and IFNα Expression in Childhood-onset Systemic Lupus Erythematosus

Abstract #1273: An Investigation of Traumatic Events and Mental Health in cSLE

Abstract #1274: Comparing Performance-Based Measures and Self-Reported Questionnaires for Assessment of Executive Function for Youth with Childhood-Onset Systemic Lupus Erythematosus

Abstract #1278: The Effects of Fatigue on Self-Reported Mental and Physical Health in Childhood-Onset Systemic Lupus Erythematosus: A Cross-Sectional Study

Abstract #1279: Cerebrovascular Accidents in Pediatric and Adult Systemic Lupus Erythematosus: A Comparison of Epidemiology and Outcomes

Abstract #1280: Abnormal Cortical Gyrification Patterns in Adolescents with Childhood-onset SLE: Early Associations with Perceived Fatigue

Abstract #1504: Novel Analytes Associated with Cognitive Impairment in Patients with Systemic Lupus Erythematosus: Serum S100A8/A9, MMP-9 and IL-6

Abstract #1506: Cognitive Impairment Prevalence and Most Affected Domains in Patients with SLE by the ACR Comprehensive Neuropsychological Battery

Monday, Nov. 18

Poster Session C, 10:30 AM-12:30 PM, Poster Hall:

Abstract #1788: Memory B Cell Activation and Dysregulation in Systemic Lupus Erythematosus

Abstract #2380: Characterizing SLE Patients into Type 1 and Type 2 Disease States: Insights from a Single Lupus Cohort

Research Conducted by Lupus Therapeutics and the Lupus Clinical Investigators Network (LuCIN)

Lupus Therapeutics, the clinical affiliate of the Lupus Research Alliance, oversees the Lupus Clinical Investigators Network (LuCIN), consisting of 50+ premier, leading medical research institutions in North America, comprised of 200+ providers with expertise in lupus care and clinical trials. The following studies are based on annual surveys of LuCIN investigators and research teams on promoting equity in lupus clinical trials and identifying trial barriers and solutions.

POSTERS

Saturday, Nov. 16

Abstract 0180: Collaborative Solutions to Lupus Trial Challenges for Underrepresented Participant Recruitment & Engagement: Perspectives from the Lupus Clinical Investigators Network (LuCIN)
Poster Session A, 10:30 AM-12:30 PM, Poster Hall

Sunday, Nov. 17

Abstract #1039: Through the LuCIN Lens: Defining Barriers and Forging Solutions for Lupus Clinical Trials in North America
Poster Session B, 10:30 AM-12:30 PM, Poster Hall

Clinical Research Supported by Lupus Therapeutics and LuCIN

The primary goal of Lupus Therapeutics and LuCIN is to accelerate and enhance the quality of lupus clinical trials through clinical expertise, advisory services, patient engagement and partnership/collaboration with biopharmaceutical companies and research partners. Lupus Therapeutics and LuCIN are involved in nearly 25% of active lupus clinical trials. Fifteen Lupus Therapeutics/LuCIN-supported programs and collaborations are being presented at ACR Convergence 2024:

ORAL PRESENTATIONS

Sunday, Nov. 17
Abstract #1773: Safety and Efficacy of CABA-201, a Fully Human, Autologous 4-1BB Anti-CD19 CAR T Cell Therapy in Patients with Immune-Mediated Necrotizing Myopathy and Systemic Lupus Erythematosus from the RESET-MyositisTM and RESET-SLETM Clinical Trials
3:30-3:45 PM, Room 145AB

Monday, Nov. 18
Abstract #2577: Efficacy and Safety of ABBV-599 (Elsubrutinib and Upadacitinib Combination) and Upadacitinib Monotherapy for the Treatment of Systemic Lupus Erythematosus: Results Through 104 Weeks in a Long-Term Extension Study
1:30-1:45 PM, Room 146AB

Abstract #2580: Safety and Efficacy of Subcutaneous Ianalumab (VAY736) for up to 68 Weeks in Patients with Systemic Lupus Erythematosus: Results from Phase 2 Study
2:15-2:30 PM Room 146AB

Tuesday, Nov. 19

***LATE-BREAKING ABSTRACT***

Abstract #L16: Dapirolizumab Pegol Demonstrated Significant Improvement in Systemic Lupus Erythematosus Disease Activity: Efficacy and Safety Results of a Phase 3 Trial

8:00-9:30 AM, 146AB

POSTERS

Saturday, Nov. 16

Poster Session A, 10:30 AM-12:30 PM, Poster Hall:

Abstract #0087: SYNCAR: An Engineered IL-2/IL-2R-system That Selectively Enhances CD19 CAR T Cells to Deplete B Cells and Provide Therapeutic Benefit in SLE and RA Mouse Models Without Lymphodepletion

Abstract #0324: Correlative Studies of CABA-201, a Fully Human, Autologous 4-1BB Anti-CD19 CAR T Cell Therapy in Patients with Immune-Mediated Necrotizing Myopathy and Systemic Lupus Erythematosus from the RESET-MyositisTM and RESET-SLETM Clinical Trials

Abstract #0620: Clinical Efficacy and Patient-Reported Outcomes in Anti-Ro/Sjögren’s Syndrome–Related Antigen a Antibody–Positive Patients with Active SLE Treated With Deucravacitinib in the Phase 2 PAISLEY Trial

Abstract #0659: Obinutuzumab Benefits Patients with Active Lupus Nephritis Irrespective of Baseline Proteinuria Severity: A Post Hoc Analysis of a Phase II Trial

Abstract #0662: Deucravacitinib, a First-in-Class, Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in SLE: Efficacy by Baseline Demographics and Disease Characteristics in the Phase 2 PAISLEY Trial

Abstract #0671: Effect of Litifilimab on Cutaneous Lupus Disease Area and Severity Index–Activity (CLASI-A) Subcomponents and Physician Global Assessment–Skin (PGA–Skin) in Patients with Cutaneous Lupus Erythematosus (CLE) in a Phase 2 Study

Sunday, Nov. 17

Poster Session B, 10:30 AM-12:30 PM, Poster Hall:

Abstract #1496: Dysregulated Serum Cytokines in Association with Clinical Manifestations in Patients with Systemic Lupus Erythematosus

Abstract #1552: Kinetics of Mucocutaneous and Musculoskeletal Responses to Deucravacitinib in Patients with Active SLE in the Phase 2 PAISLEY Trial

Abstract #1553: Safety, Pharmacokinetics, Clinical Efficacy and Exploratory Biomarker Results from a Randomized, Double-Blind, Placebo-Controlled Phase 1b Study of Enpatoran in Active Systemic and Cutaneous Lupus Erythematosus (SLE/CLE)

Monday, Nov. 18

Poster Session C, 10:30 AM-12:30 PM, Poster Hall:

Abstract #2425: Ianalumab Induced Durable Depletion of Circulating B Cell Subsets and Associated Changes in B Cell and Neutrophil Transcriptomic and Proteomic Profiles in Patients with Systemic Lupus Erythematosus: 52-Week Treatment Results from a Phase 2 Trial

Abstract #2430: Dapirolizumab Pegol Impacts Important Immunologic Pathways in Systemic Lupus Erythematosus: Pharmacodynamic Analysis of T Cell and Antigen Presenting Cell Pathways from a Phase 2b Trial

About Lupus
Lupus is a chronic, complex autoimmune disease that affects millions of people worldwide. In lupus, the immune system, meant to defend against infections, produces autoantibodies that mistake the body’s own cells as foreign, causing other immune cells to attack organs such as the kidneys, brain, heart, lungs and skin, as well as blood and joints. Ninety percent of people with lupus are women, most often diagnosed between the ages of 15-45. Black, Latinx, Indigenous, Asian and Pacific Islander people are disproportionately affected by lupus and more likely to experience severe lupus symptoms.

About the Lupus Research Alliance
The Lupus Research Alliance is the largest non-governmental, non-profit funder of lupus research worldwide. The organization aims to transform treatment by funding the most innovative lupus research, fostering diverse scientific talent, and driving discovery toward better diagnostics, improved treatments and ultimately a cure for lupus. Because the Lupus Research Alliance’s Board of Directors funds all administrative and fundraising costs, 100% of all donations goes to support lupus research programs. For more information, please visit the LRA at LupusResearch.org and on social media at: X, Facebook, LinkedIn, and Instagram.

About Lupus Therapeutics
Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, aims to accelerate the development of curative treatments for all patients living with lupus. Lupus Therapeutics collaborates with premier research institutions, biopharmaceutical partners, and those living with lupus through the unprecedented Lupus Clinical Investigators Network (LuCIN) to drive rapid and meaningful progress in treatment development. The organization elevates the patient voice, engages community stakeholders, and strives for representation of the diverse lupus community in the clinical research process with the most innovative and renowned experts throughout North America. Visit LupusTherapeutics.org for more information.

# # #

Media Contacts:
Margy Meislin, Lupus Research Alliance
MMeislin@lupusresearch.org

Caren Begun, TellMed Strategies
Caren.Begun@tmstrat.com

END

ELSE PRESS RELEASES FROM THIS DATE:

Satellite imagery may help protect coastal forests from climate change

2024-11-04

Sea-level rise caused by climate change poses a serious and often unpredictable threat to coastal forests, and new tools are needed to help mitigate damage and allocate conservation resources. A new study from North Carolina State University and the United States Geological Survey (USGS) details how satellite imagery may help identify forested areas that are being transformed into marshes and open water by sea-level rise, a process known as regime change. Marcelo Ardón, associate professor at NC State and co-author of a paper on the study, ...

The secrets of baseball's magic mud

2024-11-04

EMBARGOED UNTIL MONDAY NOVEMBER 4 AT 3:00 P.M. ET The unique properties of baseball’s famed “magic” mud have never been scientifically quantified — until now. In a new paper in Proceedings of the National Academy of Sciences (PNAS), researchers at the University of Pennsylvania School of Engineering and Applied Science (Penn Engineering) and School of Arts & Sciences (SAS) reveal what makes the magic mud so special. “It spreads like a skin cream and grips like sandpaper,” says Shravan Pradeep, the paper’s first author and a postdoctoral researcher in the labs of Douglas J. ...

Toddlers understand concept of possibility

2024-11-04

Children too young to know words like “impossible” and “improbable” nonetheless understand how possibility works, finds new work with two- and three-year-olds. The findings, the first to demonstrate that young children distinguish between improbable and impossible events, and learn significantly better after impossible occurrences, is newly published in Proceedings of the National Academy of Sciences. “Even young toddlers already think about the world in terms of possibilities,” said co-author Lisa Feigenson, co-director of the Johns Hopkins University Laboratory for Child Development. “Adults do this all the time and here we wanted ...

Small reductions to meat production in wealthier countries may help fight climate change, new analysis concludes

2024-11-04

Scientists and environmental activists have consistently called for drastic reductions in meat production as a way to reduce emissions and, in doing so, combat climate change. However, a new analysis concludes that a smaller reduction, borne by wealthier nations, could remove 125 billion tons of carbon dioxide—exceeding the total number of global fossil fuel emissions over the past three years—from the atmosphere. Small cutbacks in higher-income countries—approximately 13% of total production—would reduce the amount of land needed for cattle grazing, the researchers note, allowing forests to naturally ...

Scientists determine why some patients don’t respond well to wet macular degeneration treatment, show how new experimental drug can bridge gap

2024-11-04

**EMBARGOED FOR RELEASE UNTIL NOV. 4 AT 3:00 P.M. EST** A new study from researchers at Wilmer Eye Institute, Johns Hopkins Medicine explains not only why some patients with wet age-related macular degeneration (or “wet” AMD) fail to have vision improvement with treatment, but also how an experimental drug could be used with existing wet AMD treatments to save vision. Wet AMD, one of two kinds of AMD, is a progressive eye condition caused by an overgrowth of blood vessels in the retina, the light-sensing tissue in ...

Did the world's best-preserved dinosaurs really die in 'Pompeii-type' events?

2024-11-04

Between about 120 million and 130 million years ago, during the age of dinosaurs, temperate forests and lakes hosted a lively ecosystem in what is now northeast China. Diverse fossils from that time remained pretty much undisturbed until the 1980s, when villagers started finding exceptionally preserved creatures, which fetched high prices from collectors and museums. This started a fossil gold rush. Both locals and scientists have now dug so much, their work can be seen from space―perhaps the most extensive paleontological excavations anywhere. By the 1990s, it was clear that the so-called Yixian ...

Not the usual suspects: Novel genetic basis of pest resistance to biotech crops

2024-11-04

If left unchecked, insect pests can devastate crops. To minimize damage and reduce the need for insecticide sprays, crops have been genetically engineered to produce bacterial proteins that kill key pests but are not harmful to people or wildlife. However, widespread planting of such transgenic crops has led to rapid adaptation by some pests. A new study in the Proceedings of the National Academy of Sciences reveals a novel genetic basis of resistance to transgenic crops in one of the most important crop pests in the United States. Researchers from the University of Arizona Department of Entomology in the College of Agriculture, Life and Environmental Sciences used genomics to investigate the ...

Jill Tarter to receive Inaugural Tarter Award for Innovation in the search for life beyond earth

2024-11-04

Jill Tarter to Receive Inaugural Tarter Award for Innovation in the Search for Life Beyond Earth November 4, 2024, Mountain View, CA – Renowned astronomer, Dr. Jill Tarter, SETI Institute co-founder and pioneering SETI researcher, will be honored with the inaugural Tarter Award for Innovation in the Search for Life Beyond Earth at the SETI Institute’s 40th Anniversary celebration on November 20, 2024, in Menlo Park, CA. This new award recognizes individuals whose projects or ideas significantly advance humanity’s search for extraterrestrial life and intelligence. The Tarter Award honors contributions ...

Survey finds continued declines in HIV clinician workforce

2024-11-04

November 4, 2024 — The supply of healthcare professionals available to provide HIV care continues to decline, even as the need for HIV care and prevention is expected to increase, reports a survey study in the November/December issue of The Journal of the Association of Nurses in AIDS Care (JANAC). The official journal of the Association of Nurses in AIDS Care, JANAC is published in the Lippincott portfolio by Wolters Kluwer. "Our study provides new insights into the numbers and characteristics of clinicians who will be available to provide HIV care in the coming years. This information ...

Researchers home in on tumor vulnerabilities to improve odds of treating glioblastoma

2024-11-04

A team led by researchers at the University of Toronto has uncovered new targets that could be the key to effectively treating glioblastoma, a lethal type of brain cancer. These targets were identified through a screen for genetic vulnerabilities in patient-derived cancer stem cells that represent the variability found in tumours. Glioblastoma is the most common type of brain cancer in adults. It is also the most challenging to treat due to the resistance of glioblastoma cancer stem cells, from which tumours grow, to therapy. Cancer stem cells that survive after a tumour is treated go on to form new tumours that do not respond to further treatment. “Glioblastoma tumors have ...